BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent
UK Ruling Saw Local Counterpart Of European Apixaban Patent Declared Invalid
Executive Summary
While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.